May 13, 2022—Abbott has received FDA clearance for its Alinity m STI assay. The test simultaneously detects and differentiates four sexually transmitted infections—Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium—from one swab sample or urine sample collected in a health care setting by either a clinician or the patient.
“Over the past several years, STI cases have been on the rise, and we expect to see increasing rates as people resume testing after delaying during the pandemic,” Kathryn Becker, PhD, Abbott’s global director of scientific affairs innovation, said in a press statement. “With that comes an increased need for effective and efficient testing. This four-plex STI test gives health care providers a more holistic picture of someone’s health in a single test, helping to support the best treatment plan to address these common STIs individually or as co-infections.”
The Alinity m STI assay runs on the company’s high-volume Alinity m molecular PCR system.